NBIX vs. UTHR

In the year-to-date period, NBIX achieves a 2.80% return, which is significantly lower than UTHR's 62.60% return. Over the past 10 years, NBIX has outperformed UTHR with an annualized return of 18.69%, while UTHR has yielded a comparatively lower 10.37% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Neurocrine Biosciences, Inc. (NBIX) and United Therapeutics Corporation (UTHR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current NBIX Sharpe Ratio is 0.39, which is lower than the UTHR Sharpe Ratio of 1.55. The chart below compares the historical Sharpe Ratios of NBIX and UTHR, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither NBIX nor UTHR has paid dividends to shareholders.

The maximum NBIX drawdown since its inception was -97.21%, roughly equal to the maximum UTHR drawdown of -93.18%. Use the drawdown chart below to compare losses from any high point for NBIX and UTHR. For additional features, visit the drawdowns tool.

The current volatility for Neurocrine Biosciences, Inc. (NBIX) is 7.24%, while United Therapeutics Corporation (UTHR) has a volatility of 8.53%. This indicates that NBIX experiences smaller price fluctuations and is considered to be less risky than UTHR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Neurocrine Biosciences, Inc. and United Therapeutics Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.